Verve Therapeutics, Inc. Stock News

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, tod

Here we discuss three stocks - CDXS, PGEN, VERV - engaged in the field of scientific biology that investors may keep a tab of as these have the potential to generate wealth for them going forward.

Global IPOs have raised $453 billion in proceeds, representing a 67% increase year-over-year and a more than doubling from 2019 levels.

Verve Therapeutics, Inc. (NASDAQ:VERV) Director Burt A. Adelman bought 4,700 shares of Verve Therapeutics stock in a transaction dated Thursday, December 2nd. The shares were bought at an average cost of $31.34 per share, with a total value of $147,298.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can []

Royal Bank of Canada bought a new position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 7,100 shares of the companys stock, valued at approximately $428,000. A number of other hedge funds also recently made changes to their positions []

Verve Therapeutics, Inc. (NASDAQ:VERV)s share price rose 11.6% during trading on Tuesday after an insider bought additional shares in the company. The company traded as high as $36.04 and last traded at $35.90. Approximately 7,700 shares traded hands during trading, a decline of 98% from the average daily volume of 401,452 shares. The stock had []

Verve Therapeutics (NASDAQ:VERV) lock-up period will end on Tuesday, December 14th. Verve Therapeutics had issued 14,035,789 shares in its IPO on June 17th. The total size of the offering was $266,679,991 based on an initial share price of $19.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade []

Verve Therapeutics, Inc. (NASDAQ:VERV) Director Burt A. Adelman acquired 4,700 shares of the stock in a transaction dated Thursday, December 2nd. The stock was acquired at an average price of $31.34 per share, for a total transaction of $147,298.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can []

Verve Therapeutics, Inc. (NASDAQ:VERV)s stock price dropped 5.7% on Thursday . The company traded as low as $30.89 and last traded at $31.41. Approximately 9,162 shares changed hands during trading, a decline of 98% from the average daily volume of 401,011 shares. The stock had previously closed at $33.31. VERV has been the subject of []

CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics , Inc., (Nasdaq: VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Allison Dorval has been appointed as chief financial officer. Ms. Dorval joins Verve from Voyager Therapeutics and brings more than 20 years of leadership experience in finance, accounting, financial reporting and investor relations.

Verve Therapeutics, Inc. (NASDAQ:VERV) Stock analysts at William Blair lowered their FY2021 earnings estimates for shares of Verve Therapeutics in a report issued on Wednesday, November 10th. William Blair analyst R. Prasad now anticipates that the company will post earnings of $0.84 per share for the year, down from their previous forecast of $0.94. []

The biotech stock rose nearly $7 a share from Monday through Thursday.

They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.

CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, to

Verve Therapeutics Inc (NASDAQ: VERV) has reported new preclinical data from 36 non-human primates (NHPs) with its lead candidate, VERVE-101. VERVE-101 is a potential single-course gene-editing tre